MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
0.8405
+0.0157
+1.90%
Opening 10:47 11/19 EST
OPEN
0.8300
PREV CLOSE
0.8248
HIGH
0.8510
LOW
0.8300
VOLUME
8.30K
TURNOVER
--
52 WEEK HIGH
2.910
52 WEEK LOW
0.7800
MARKET CAP
3.72M
P/E (TTM)
-0.3400
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPRX last week (1109-1113)?
Weekly Report · 3d ago
Analysts Are Bullish on These Healthcare Stocks: TuHURA Biosciences (HURA), Kiora Pharmaceuticals (KPRX)
TipRanks · 4d ago
Kiora Pharmaceuticals Faces High-Stakes Risk in KIO-401 Deal with Senju as 2040 Regulatory Deadline Looms
TipRanks · 6d ago
Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and KIO-401 In-Licensing
NASDAQ · 6d ago
Weekly Report: what happened at KPRX last week (1102-1106)?
Weekly Report · 11/09 10:17
Weekly Report: what happened at KPRX last week (1026-1030)?
Weekly Report · 11/02 10:17
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Stryker (SYK)
TipRanks · 10/30 18:50
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/29 17:06
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.